EN DE
Watch Ortin Global Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ortin Global Limited (ORTINGLOBE) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Ortin Global Limited stock ₹7.11, price ₹13.98, that is 49.1% below the price, quality 30 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE749B01020

OG Ortin Global Limited logo Thin data Nov 10, 2026

Ortin Global Limited

ORTINGLOBE · NSE
Very expensive, weak quality

Our calculation puts a fair price 49% below what the stock costs today.

Moderate debt
Revenue last quarter 60% below a year ago.
Fair value ₹7.11 · Strongly overvalued
Quality 30/100
Weak Growth (revenue 5y −58.5 %/yr in INR)
Negative free cash flow
Trails peers (0/7)
Narrow moat 8/100
Thin data
Estimate
Watch Ortin Global Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹36.80 ₹9.79 Fair Value ₹7.11 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ₹9.79 – ₹36.80 · fair‑value band ₹5.33 – ₹8.89 · the ₹13.98 price screens above the ₹7.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Ortin Global in your weekly email

Every Wednesday you see whether Ortin Global is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India.

Show moreShow less

The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides.

Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products.

In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products.

Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents.

Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate.

The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Stock analysis

Ortin Global Limited (ORTINGLOBE) currently trades at ₹13.98, while our estimate is ₹7.11, 49% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹5.33 (bear) to ₹8.89 (bull), the price of ₹13.98 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Ortin Global Limited reported revenue of ₹1.0M in FY2026 versus ₹82.3M in FY2022, a compound −66.8%/yr. Reported net income was −₹7.4M in FY2026.

Key figures

Market cap ₹114M (≈ $1.2M) Micro · EPS (TTM) ₹−1.12 · Return on equity −46.1% · Return on assets (EBIT) −22.1% (5-year average) · Operating margin −2,091% · Revenue (TTM) ₹356K · Revenue growth (YoY) −59.8% · Free cash flow −₹5.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (medium confidence).

What moves the price

The share trades about 30% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −49%, ORTINGLOBE screens richer than that median.

Fair Value

Bear ₹5.33 Fair Value ₹7.11 Bull ₹8.89
Price ₹13.98 · Downside -49.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 23
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 57
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 43
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−70.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−74.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−58.5%
Start year 2021 (pandemic). Over 10 years: −47.5% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.8% (2021) → −1,030.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

ORTINGLOBE screens overvalued: fair value 49% below the price. Compare with Merck KGaA →

Compare Ortin Global Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −49.1% · Bottom 25%
Profitability
Return on assets −15.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −59.8% · Bottom 25%
Balance sheet
Debt / equity 0.81× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 9.19× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)59 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs ORTINGLOBE
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs ORTINGLOBE
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs ORTINGLOBE
Haleon plc HLN $9.06 $8.62 −5% vs ORTINGLOBE
Merck KGaA MRK €149.35 €109.18 −27% vs ORTINGLOBE
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs ORTINGLOBE
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs ORTINGLOBE
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs ORTINGLOBE
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs ORTINGLOBE
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs ORTINGLOBE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ortin Global Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ortin Global Limited Fair Value". https://www.fairvalue-calculator.com/stock/ORTINGLOBE

Frequently asked questions

Is Ortin Global Limited (ORTINGLOBE) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ₹7.11 versus a price of ₹13.98, about 49% lower (overvalued).
What is the fair value of ORTINGLOBE?
Our estimate for Ortin Global Limited is ₹7.11 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹13.98.
What is the quality score of ORTINGLOBE?
Ortin Global Limited has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ortin Global Limited (ORTINGLOBE)?
Our calculated price target is the estimate of ₹7.11 (as of Nov 10, 2026). Cautious scenario ₹5.33, optimistic scenario ₹8.89. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Ortin Global Limited stock forecast for 2026?
Our estimate puts fair value at ₹7.11, about 49% lower versus a price of ₹13.98 (overvalued). Cautious scenario ₹5.33, optimistic scenario ₹8.89. The calculation is refreshed regularly with new filings.
What is the revenue of Ortin Global Limited (ORTINGLOBE)?
Ortin Global Limited reported trailing-twelve-month revenue of about ₹356K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Ortin Global Limited (ORTINGLOBE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ortin Global Limited it is ₹7.11 per share (as of Nov 10, 2026), against a price of ₹13.98.
Is Ortin Global Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ORTINGLOBE trades above its calculated fair value: price ₹13.98, fair value ₹7.11, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORTINGLOBE?
No. The price is what the market pays today (₹13.98); the fair value is what the company's own numbers justify (₹7.11). For Ortin Global Limited the two are ₹6.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ortin Global Limited worth?
The market values Ortin Global Limited at about ₹114M (market capitalisation, as of Nov 10, 2026). Per share that is ₹13.98; our models calculate a fair value of ₹7.11 per share.
What do the bullish and bearish scenarios say about ORTINGLOBE?
Our models span a range for Ortin Global Limited: cautious scenario ₹5.33, base ₹7.11, optimistic ₹8.89 per share (as of Nov 10, 2026, price ₹13.98). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ortin Global Limited (ORTINGLOBE)?
Balance-sheet figures for Ortin Global Limited (as of Nov 10, 2026): return on equity −46.1%, debt of 0.81 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is ORTINGLOBE from its 52-week high?
Ortin Global Limited trades at ₹13.98, about 30% below its 52-week high of ₹19.92 and 25% above the low of ₹11.19 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹7.11 is for.
Which stocks are comparable to Ortin Global Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ortin Global Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹13.98, calculated fair value ₹7.11 (−49%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Ortin Global Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ortin Global Limited (ORTINGLOBE)?
The closing price on Nov 9, 2026 was ₹13.98. Our estimate is ₹7.11, about 49% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ortin Global Limited right now?
The price sits above even our optimistic bull case (₹8.89). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Ortin Global Limited

How large is the market capitalisation of Ortin Global Limited (ORTINGLOBE)?
The market capitalisation of Ortin Global Limited is ₹114M (≈ $1.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Ortin Global Limited (ORTINGLOBE)?
Earnings per share at Ortin Global Limited are ₹−1.12. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Ortin Global Limited (ORTINGLOBE)?
The return on equity (ROE) of Ortin Global Limited is −46.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ortin Global Limited (ORTINGLOBE)?
On an EBIT basis the return on assets of Ortin Global Limited is −22.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ortin Global Limited (ORTINGLOBE)?
The operating margin of Ortin Global Limited is −2,091% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ortin Global Limited (ORTINGLOBE)?
Revenue at Ortin Global Limited is growing −59.8% versus a year earlier (3y avg −74.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ortin Global Limited (ORTINGLOBE) generate?
The free cash flow of Ortin Global Limited is −₹5.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ortin Global Limited (ORTINGLOBE) carry?
The net debt of Ortin Global Limited is ₹4.0M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ortin Global Limited in the live analysis

One click puts Ortin Global Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.